Overview

BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy

Status:
Active, not recruiting

Trial end date:
2021-06-01

Target enrollment:

Participant gender:

Summary

This is a multi-center Phase II study to determine the safety and efficacy of nivolumab when given in combination with cisplatin and gemcitabine as neoadjuvant treatment in patients with muscle-invasive bladder cancer (MIBC) prior to standard of care radical cystectomy. Patients will receive neoadjuvant treatment with nivolumab in combination with gemcitabine-cisplatin (GC) every 3 weeks for 4 treatment cycles over 12 weeks followed by standard of care radical cystectomy.

Phase:

Phase 2

Details

Lead Sponsor:

Masonic Cancer Center, University of Minnesota

Collaborator:

Bristol-Myers Squibb

Treatments:

Antibodies, Monoclonal
Cisplatin
Gemcitabine
Nivolumab